Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Value Health. 2013 Sep-Oct;16(6):10.1016/j.jval.2013.07.006. doi: 10.1016/j.jval.2013.07.006

Figure 6.

Figure 6

Cost-effectiveness acceptability curve. PR48= peginterferon-ribavirin regimen; BOC/RGT = Response Guided Therapy; BOC/PR48 peginterferon–ribavirin-boceprevir regimen.